Statistics for Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy : JANUS 1 and 2 randomized phase III studies
Total visits
| views | |
|---|---|
| Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy : JANUS 1 and 2 randomized phase III studies | 94 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
File Visits
| views | |
|---|---|
| Ruxolitinib + capecitabine in advanced-metastatic pancreatic cancer after disease progression-intolerance to first-line therapy JANUS 1 and 2 randomized phase III studies.pdf | 11 |
Top country views
| views | |
|---|---|
| United States | 41 |
| Chile | 19 |
| Israel | 1 |
| Mexico | 1 |
| Netherlands | 1 |
Top city views
| views | |
|---|---|
| Miami | 37 |
| Santiago | 12 |
| Concepcion | 3 |
| Macul | 3 |
| Alameda | 2 |
| Campbell | 1 |
| Punta Arenas | 1 |
| Sacramento | 1 |
| Tel Aviv | 1 |
| Zapopan | 1 |